ausperbio.com
Get leads like Ausperbio — and thousands more
Build targeted lists by tech stack, traffic, and more
AusperBio: The 7-Person Biotech Taking on Hepatitis B
A deep dive into the micro-cap biotech with a macro mission: cure HBV.
In a biotech landscape dominated by billion-dollar giants, AusperBio is making a quiet but audacious bet: that a team of just seven people can crack the code to curing Hepatitis B. Armed with a proprietary oligonucleotide platform and Phase II momentum, they're not just building a drug—they're building a case for focused, capital-efficient innovation.
"AusperBio isn't playing the volume game—they're playing the precision game, targeting HBV with a focused, capital-efficient strategy."
The HBV Cure Challenge
Hepatitis B affects over 300 million people globally, yet current treatments suppress rather than cure. AusperBio's Med-Oligo™ ASO platform aims to change that by directly targeting viral RNA. With keywords like '乙肝临床三期药物' (Hepatitis B Phase III drug) driving search traffic, they're clearly targeting a high-intent, medical-professional audience—not the general public.
The Data-Driven Reality
With 1,334 monthly visits and a global rank of #9.7M, AusperBio's web presence is minimal—typical for a clinical-stage biotech. However, the traffic composition tells a story: 58% direct traffic suggests strong brand recall among investors and industry insiders, while 21% organic search indicates targeted, keyword-driven interest. The 'undefined' country data is a red flag for international SEO, but likely reflects their early-stage, China-focused operations.
The company's leadership team—led by CEO Guofeng Cheng and CSO Chris Yang—brings deep expertise in oligonucleotide therapeutics. Their SVP of Research and VP of Clinical Development round out a lean but experienced C-suite. This isn't a founder-led science experiment; it's a calculated assault on a $10B+ market opportunity.
- Proprietary Med-Oligo™ ASO platform for targeted delivery
- Phase II clinical stage for HBV, with pipeline potential in metabolic & genetic disorders
- Lean operational model: 7 employees, $1.1M revenue, focused execution
- Traffic dominated by direct (58%) and organic (21%)—minimal paid noise
- Strong China keyword footprint, hinting at regional regulatory and market focus
The Micro-Cap Biotech Playbook
AusperBio isn't trying to be a platform giant—it's proving that focused execution, proprietary tech, and Phase II validation can outmaneuver bigger, slower competitors. For investors, this is a high-risk, high-reward bet on a team that knows exactly what it's solving.
What tech stack does Ausperbio use?
How much traffic does Ausperbio get?
Traffic & Engagement
Traffic Sources
Where is Ausperbio's audience located?
What keywords does Ausperbio rank for?
5 keywordsHow is Ausperbio's SEO?
Meta Tags
Ausperbio
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.
What is Ausperbio's revenue?
Who works at Ausperbio?
Loading leads...
What do customers think of Ausperbio?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Ausperbio
What is Ausperbio's Revenue?
What does Ausperbio do?
How fast is Ausperbio growing?
What technologies does Ausperbio use?
Who are Ausperbio's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Ausperbio?
Contact Information
Export ausperbio.com Data
Download the complete tech stack, analytics, leads, and company data for ausperbio.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About ausperbio.com
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, we strive to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, and to transform patient lives.
Company Overview
Contact ausperbio.com
Email Addresses
Phone Numbers
Technology Stack
ausperbio.com uses 2 technologies across their website including Bootstrap, Vue.js.
CSS Frameworks
Bootstrap
Frontend Frameworks
Vue.js
Traffic & Audience
ausperbio.com receives approximately 1.3K monthly visitors and ranks #9,720,379 globally. The website has a bounce rate of 32% with visitors viewing an average of 2.3 pages per visit. Users spend an average of 0:56 on the site.
The majority of ausperbio.com's traffic comes from .
Frequently Asked Questions
What is ausperbio.com?
What technologies does ausperbio.com use?
How do I contact ausperbio.com?
How popular is ausperbio.com?
Related Searches
This page provides publicly available information about ausperbio.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit ausperbio.com directly at https://ausperbio.com.